11 February 2019 in BioMed Research International
KSKatarzyna Siemiątkowska
Introduction. Rheumatoid arthritis (RA) is a long-term disorder significantly impairing the somatic, emotional, and psychological functioning of its sufferers. Previous research has shown that affected individuals are characterized by an increased level of anxiety and depression. Currently, there are two main treatment schemes for RA; the first uses anti-inflammatory drugs, and the second utilizes biologic agents. This begs the question whether sufferers differ in intensities of pain, anxiety, and depression depending on the type of treatment and what the determinants of these affective states in patients treated using different methods are. Methods. The study comprised 85 patients affected by RA (including 57 receiving biologically inactive medication). Research participants filled out a set of questionnaires measuring levels of anxiety and depression, intensity of experienced pain, strategies of coping with pain, and ego resiliency. Results. The collected data was analyzed through intergroup comparisons, calculating simple correlation coefficients, developing and solving regression equations. The results imply that the choice of treatment differentiates the intensity of pain experienced by patients. Those receiving biologic agents reported lower levels of pain compared to those taking anti-inflammatory medication. It has also been noted that there are distinct configurations of conditions conducive to anxiety and depression in both anti-inflammatory and biologic agent groups. Discussion. The observed constellation of dependencies between variables indicates that the choice of treatment scheme differentiates pain levels. This confirms the assumption that pain intensity, coping strategies, and ego resiliency depend on the severity of anxiety and depression.
27 September 2019 in Medical Principles and Practice
Objective: Ego-resiliency is attributed the status of a “meta resource” that is responsible for a flexible selection of coping strategies depending on the requirements of a specific difficult situation. A considerably burdensome critical life event is the development of a chronic illness such as rheumatoid arthritis (RA). Apart from coping with the symptoms, a fundamental task confronting patients is maintaining their quality of life. This raises the question of whether ego-resiliency serves as a mediator between coping strategies and quality of life. Materials and Methods: 210 RA patients were invited to participate in this study. They were requested to complete a questionnaire that included the Satisfaction with Life scale, the stress coping inventory Mini-COPE, and the Ego-Resiliency scale. The collected data were analyzed by a simple mediation procedure and estimation of simple correlation coefficients. Results: The analysis demonstrated that ego-resiliency (r = 0.46; p < 0.001) and emotion-focused coping (r = 0.39; p < 0.001) determined life satisfaction. Additionally, ego-resiliency mediated the relation between emotion-oriented coping strategies and life satisfaction. Partial mediation was observed (a = 0.45**; b = 0.36**; c = 0.39**; c’ =0.22**; R2 = 0.24; F = 35.65; p < 0.001). Conclusion: Our observations partly support the assumption about a controlling role of ego-resiliency in the process of selecting coping strategies according to demands of situations.
1 December 2019 in Journal of Education, Health and Sport
Introduction: There are many factors that affect temporomandibular joint dysfunction. These may include, among others: structural and postural disorders, bruxism, and occlusive abnormalities. In addition, an important aspect are psychological factors that, as a result of stress, can affect temporomandibular joint disorders through hyperactivity of the muscles, followed by biomechanical changes and related pain. These factors can lead to the production of neurotransmitters that disturb the balance of serotonin and catecholamines. Aim: Literature review to determine the relationship between temporomandibular joint disorders and psychological disorders in pediatric patients Material and methods: Based on the Research Gate, PubMed and Google Schoolar databases, a review of scientific papers was performed using the keywords: (temporomandibular joint), (stress, bruxism, mental disorders). Articles from the last 5 years have been analyzed. Results: Higher levels of anxiety are observed in patients with temporomandibular joint disorders. There is also a higher incidence of depression and chronic stress. Conclusions: Available literature shows the relationships between dysfunctions within the temporomandibular joint and mental disorders of the patient. However, research in this area should continue to show more detailed information regarding both the general relationship between the abovementioned aspects and the relationship between individual temporomandibular joint disorders and psychological aspects.
9 August 2018 in BioMed Research International
30 November 2020 in Aktualności Neurologiczne
Introduction: Isolation of two compounds, tetrahydrocannabinol (THC) and cannabidiol (CBD), contributed to an increased interest in the use of marijuana for medicinal purposes. It was then that research on the effects of marijuana on the course of different diseases began. Aim: The aim of this paper was to analyse the use of cannabinoids in the treatment of children with autism spectrum disorder. Results: There are different methods for cannabinoid administration. Researchers use various preparations with doses ranging between 0.04 mg to 900 mg. Preliminary studies are conducted on animal models, usually in genetically modified mice. Cannabinoids have been found to have a positive effect on social and emotional behaviours of children, as well as to show anxiolytic and antipsychotic effects. Cannabidiol plays an important role in the secretion of vasopressin and oxytocin. Some patients experience adverse effects. Antidepressant and anticonvulsant effects have been observed in patients with neurological and mental disorders. Conclusions: Cannabinoid therapy is not the standard of care in children with autism spectrum disorders, and the doses used vary significantly. There is evidence for the positive effects of cannabinoids in patients with comorbidities. It is possible that cannabinoids have an anxiolytic effect and allow for a reduced use of antipsychotics in the analysed group of patients. Antidepressant and anticonvulsant effects have also been observed. Furthermore, it was shown that CBDs administered in mice with Dravet syndrome improve social behaviour, dysfunction of which is one of the central symptoms of autism spectrum disorder.